Access cutting-edge neovascular age-related macular degeneration treatment through this clinical trial at a research site in Mesa. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Mesa location
Preparing your pre-screening questions…
Access neovascular age-related macular degeneration specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related neovascular age-related macular degeneration treatment provided free
Check if you qualify for this neovascular age-related macular degeneration clinical trial in Mesa, AZ
No-Cost Study Care
Local to Mesa
Convenient for AZ residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. The purpose of this study is to assess how safe and effective Surabgene Lomparvovec is in treating participants with Neovascular age-related macular degeneration (nAMD). Surabgene Lomparvovec (ABBV-RGX-314) is an investigational gene therapy being developed for the treatment of neovascular age-related macular degeneration (nAMD). Participants will be placed into 1 of 3 groups, called treatment arms. Each group receives different treatment. Adult participants aged 50 and older years with a diagnosis of previously treated nAMD will be enrolled. Around 561 participants will be enrolled in the study at approximately 150 sites worldwide. Participants in groups 1 and 2 will receive a single subretinal dose of ABBV-RGX-314. Participants in group 3 will receive Ranibizumab as needed throughout the study. Ranibizumab will be given as an intravitreal injection (injection into the jelly-like tissue that fills the eyeball injection), and ABBV-RGX-314 will be given as a subretinal (between the retina and the back of the eye) injection. The Assessment Period begins after randomization (1:1:1) to one of the ABBV-RGX-314 treatment groups or control at Week -2 and lasts up to 5 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular monthly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Sponsor: AbbVie
Yes, this clinical trial (NCT07007065) has an active research site in Mesa, AZ that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for neovascular age-related macular degeneration treatment options in Mesa, AZ, this clinical trial (NCT07007065) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Mesa research site is actively enrolling participants for this clinical trial. You'll receive care from experienced neovascular age-related macular degeneration specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all neovascular age-related macular degeneration clinical trials near you to find additional studies recruiting in your area.
See all rheumatoid arthritis clinical trials recruiting in Mesa — not just this study.
Browse Rheumatoid Arthritis Trials in Mesa →